Pemivibart is a monoclonal antibody targeting SARS-CoV-2 spike protein used for pre-exposure prophylaxis against COVID-19 in certain immunocompromised patients. It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.
- Mechanism
- Curator reviewed · 4 references
SARS-CoV-2 entry into the host cell is mediated by the angiotensin-converting enzyme-II (ACE2) receptor, which binds to the receptor-binding domain (RBD) of the viral spike protein. Upon entry, SARS-CoV-2 replicates and causes viral pathogenicity. Pemivibart is a recombinant human monoclonal IgG1λ antibody that targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells.
- Primary indication
- Under the Emergency Use Authorization (EUA), pemivibart is approved for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of...Curator reviewed · 1 structured indication
- Formula / weight
- 147510.0 Da (approximate)
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with Pemivibart, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account